Allianz Asset Management GmbH Cuts Stock Holdings in Elanco Animal Health Incorporated $ELAN

Key Points

• Allianz Asset Management reduced its Elanco Animal Health stake by 36.8% in the second quarter, selling 172,536 shares and retaining 296,510 shares valued at approximately $7.3 million.
• Institutional ownership remains high at 97.48%, with BlackRock and Primecap Management initiating major positions while California State Teachers Retirement System significantly increased its stake.
• Elanco beat quarterly earnings and revenue estimates, reporting $0.34 EPS on $1.37 billion in revenue. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $29.09, versus a recent share price of $23.95.

Allianz Asset Management GmbH lowered its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 36.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 296,510 shares of the company's stock after selling 172,536 shares during the quarter. Allianz Asset Management GmbH owned 0.06% of Elanco Animal Health worth $7,297,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of ELAN. BlackRock Inc. bought a new position in shares of Elanco Animal Health during the second quarter valued at about $1,202,198,000. Primecap Management Co. CA purchased a new position in Elanco Animal Health during the second quarter worth about $1,118,402,000. California State Teachers Retirement System grew its position in Elanco Animal Health by 2,358.9% in the 2nd quarter. California State Teachers Retirement System now owns 14,186,139 shares of the company's stock worth $349,121,000 after purchasing an additional 13,609,203 shares in the last quarter. The Manufacturers Life Insurance Company bought a new stake in Elanco Animal Health in the 2nd quarter worth about $205,636,000. Finally, UBS Group AG increased its stake in Elanco Animal Health by 56.7% in the 3rd quarter. UBS Group AG now owns 16,468,148 shares of the company's stock valued at $331,669,000 after buying an additional 5,961,457 shares during the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Elanco Animal Health

In other Elanco Animal Health news, Director Paul Herendeen acquired 10,000 shares of the business's stock in a transaction that occurred on Friday, August 7th. The stock was bought at an average cost of $23.68 per share, with a total value of $236,800.00. Following the acquisition, the director owned 111,687 shares in the company, valued at approximately $2,644,748.16. This represents a 9.83% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Shiv O'Neill acquired 3,998 shares of the business's stock in a transaction that occurred on Tuesday, August 18th. The stock was acquired at an average cost of $23.58 per share, with a total value of $94,272.84. Following the completion of the acquisition, the insider owned 87,832 shares in the company, valued at $2,071,078.56. This trade represents a 4.77% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 63,198 shares of company stock worth $1,473,109 in the last ninety days. Insiders own 1.14% of the company's stock.

Elanco Animal Health Trading Down 2.3%

NYSE:ELAN opened at $23.95 on Wednesday. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58. The stock has a market capitalization of $11.96 billion, a PE ratio of -58.41, a price-to-earnings-growth ratio of 1.83 and a beta of 1.68. The firm's 50 day moving average is $24.63 and its 200 day moving average is $23.96. Elanco Animal Health Incorporated has a 12 month low of $18.22 and a 12 month high of $27.98.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.07. The business had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.31 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.Elanco Animal Health's revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the company earned $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Sell-side analysts expect that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ELAN has been the topic of several recent analyst reports. TD Cowen lifted their target price on shares of Elanco Animal Health from $31.00 to $32.00 and gave the stock a "buy" rating in a research report on Thursday, June 18th. UBS Group upped their target price on Elanco Animal Health from $31.00 to $33.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Weiss Ratings raised Elanco Animal Health from a "sell (d)" rating to a "sell (d+)" rating in a research report on Friday. KeyCorp lifted their price target on Elanco Animal Health from $29.00 to $30.00 and gave the stock an "overweight" rating in a report on Thursday, August 6th. Finally, Morgan Stanley boosted their price objective on Elanco Animal Health from $23.00 to $26.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Elanco Animal Health currently has a consensus rating of "Moderate Buy" and a consensus price target of $29.09.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.